Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
| ▸ | RAB9A | P51151 | 2/20 | 0.97 |
| ▸ | GRM5 | P41594 | 15/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323778 | 0.98 | NPC1 (1.00) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL28975696 | 0.93 | L3MBTL1 (0.88) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL9265040 | 0.86 | RAB9A (0.79) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL6707186 | 0.86 | RAB9A (0.79) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL6824208 | 0.86 | L3MBTL1 (0.76) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL19797902 | 0.83 | GRM5 (0.80) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL19797900 | 0.83 | GRM5 (0.80) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL10212190 | 0.82 | L3MBTL1 (0.69) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL19445791 | 0.82 | RAB9A (0.72) | L3MBTL1NPC1RAB9AGRM5 | |
| SCHEMBL23716717 | 0.81 | GRM5 (0.76) | L3MBTL1NPC1RAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975288-B2 | F2 derivatives as antibacterial agents | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975288-B2 | F2 derivatives as antibacterial agents | THE PENN STATE RESEARCH FOUNDATION (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140275192-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | THE PENN STATE RESEARCH FOUNDATION | 2014-09-18 | — | — | US | disclosed |
| US-20140275192-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | THE PENN STATE RESEARCH FOUNDATION | 2014-09-18 | — | — | US | disclosed |
| WO-2013154793-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275192-A1 | F2 DERIVATIVES AS ANTIBACTERIAL AGENTS | NR2C2, H1-10, NR2F2 | L3MBTL1 3653/4885NPC1 554/4885RAB9A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.